In addition, a VISTA agonistic antibody (4C11) could suppress allergic pulmonary inflammation in mice, indicating that targeting VISTA might be an attractive therapeutic strategy for allergic asthma (Liu et al. 2018). This evidence concerns the gene VSIR and allergic asthma.